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Abstract
BACKGROUND: Colchicine has been traditionally used for the treatment of gout. In just over the last twenty
years, colchicine has been gaining interest as a treatment for acute and recurrent pericarditis. A few small
studies have addressed the safety and efficacy of this treatment, however, a general agreement has not been
reached.
METHODS: A systematic literature review of the studies focusing on colchicine for the treatment of
pericarditis, from 1990 to present, was performed using the MEDLINE, CINAHL and Web of Science
databases. A modified validity scoring method (0-10) was applied to the studies that qualified through the
inclusion and exclusion criteria.
RESULTS: Five studies that focused on colchicine for the treatment of pericarditis met the inclusion and
exclusion criteria. There were two randomized, open-label studies (n=120 & n=84) with a validity score of
eight. There was one prospective, cohort study (n=58) with a validity score of five. There was one
retrospective, multi-center case analysis (n=119) that received a validity score of two, and a prospective case
series (n=9) with a validity score of three. All of the studies found colchicine to be effective for the treatment
of acute or recurrent pericarditis, with 1 mg daily as the most common dose. There were no reports of serious,
adverse reactions to colchicine. Diarrhea was the most common side effect. As a secondary outcome,
corticosteroids were found to be an independent risk factor for the recurrence of pericarditis in three of the
studies.
CONCLUSION: Based on this systematic review of literature, there is moderate evidence showing colchicine
to be safe and effective in the treatment of acute or recurrent pericarditis. However, a larger, double-blinded,
randomized-controlled trial is needed to further investigate this potential treatment. There is also some
evidence to support corticosteroids as an independent risk factor for the recurrence of pericarditis.
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Abstract   
 
 
BACKGROUND:  Colchicine has been traditionally used for the treatment of gout.  In 
just over the last twenty years, colchicine has been gaining interest as a treatment for 
acute and recurrent pericarditis.  A few small studies have addressed the safety and 
efficacy of this treatment, however, a general agreement has not been reached.  
METHODS:  A systematic literature review of the studies focusing on colchicine for the 
treatment of pericarditis, from 1990 to present, was performed using the MEDLINE, 
CINAHL and Web of Science databases.  A modified validity scoring method (0-10) was 
applied to the studies that qualified through the inclusion and exclusion criteria.  
RESULTS:  Five studies that focused on colchicine for the treatment of pericarditis met 
the inclusion and exclusion criteria.  There were two randomized, open-label studies 
(n=120 & n=84) with a validity score of eight.  There was one prospective, cohort study 
(n=58) with a validity score of five.  There was one retrospective, multi-center case 
analysis (n=119) that received a validity score of two, and a prospective case series (n=9) 
with a validity score of three.  All of the studies found colchicine to be effective for the 
treatment of acute or recurrent pericarditis, with 1 mg daily as the most common dose.  
There were no reports of serious, adverse reactions to colchicine.  Diarrhea was the most 
common side effect.  As a secondary outcome, corticosteroids were found to be an 
independent risk factor for the recurrence of pericarditis in three of the studies.  
CONCLUSION:  Based on this systematic review of literature, there is moderate 
evidence showing colchicine to be safe and effective in the treatment of acute or recurrent 
pericarditis.  However, a larger, double-blinded, randomized-controlled trial is needed to 
further investigate this potential treatment.  There is also some evidence to support 
corticosteroids as an independent risk factor for the recurrence of pericarditis.  
KEYWORDS:  colchicine; pericarditis. 
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The Safety and Efficacy of Colchicine for the Treatment 
of Pericarditis 
 
 
 
Introduction and Background 
 
 
 Pericarditis is characterized by inflammation of the pericardial sac, the pericardium, that lines 
the outside of the heart.1  Inflammation of the pericardium may have an infectious etiology or it may 
be due to a variety of systemic illnesses including:  autoimmune disease, uremia, neoplasm, radiation, 
drug toxicity, hemopericardium, post-cardiac surgery, myocardial or lung disease.1  It can be acute, 
chronic or recurrent in nature.  If the inflammation has an identifiable cause, then treatment will focus 
on that specific target.  However, most cases have a viral or idiopathic origin, for which only 
symptomatic, nonspecific treatment is available.  Usually, symptomatic treatment of pericarditis 
consists of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and, in rare cases, 
immunosuppressants or pericardectomy.1  Pericarditis may have a recurrence rate as high as 15 to 50 
percent after its initial episode, although the incidence of the disease is unclear, most likely due to the 
non-specific symptoms.2-5  Some patients experience recurrent or chronic symptoms even after a 
pericardectomy.4  These factors demonstrate a clear need for improved treatment for acute, chronic, 
and recurrent pericarditis.   
 Colchicine, a plant alkaloid, has been used for many years to treat acute gout attacks, chronic 
gout and acute arthritis.2, 3, 6-8  It relieves pain in acute gout and it decreases the frequency of repeated 
attacks, although the mechanism of action is not completely understood.6  It is believed that colchicine 
causes a depolymerization of tubulin, which terminates cell division by disrupting the spindle 
apparatus.  In inhibiting normal cellular function, colchicine decreases the mobility of granulocytes 
and the synthesis and release of leukotrines to affected areas in the body.  Thus, colchicine has an anti-
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inflammatory effect by decreasing the mobility of granulocytes and leukotrines.  This process also 
appears to reduce the deposition of urate crystals, the key component to gouty inflammation.6  For 
acute attacks of gout, the initial dose is 0.6-1.2 mg, followed by 0.6 mg every one to two hours.  For 
prophylaxis of attacks, the dose is approximately 0.6 mg twice daily.9  There are intravenous forms of 
colchicine, but this study will only focus on the oral form of this drug. The most common side effects 
are nausea, vomiting and diarrhea.6  In rare cases, long-term administration may lead to myopathy, 
neutropenia, aplastic anemia and alopecia.6  
 In the past two decades, colchicine has drawn increased interest as a new therapy for 
pericarditis.  Similar to gout, colchicine’s mechanism of action with pericarditis is not completely 
understood.  However, it appears to work on the same anti-inflammatory pathway by inhibiting the 
motility of granulocytes and leukotrines to the pericardium.  Along with the treatment of gout and 
arthritis, colchicine has proven to be effective in the prevention of polyserositis in the hereditary 
inflammatory disorder, Familial Mediterranean fever.10  In 1987, Rodriguez de La Serna proposed 
colchicine as a treatment for difficult cases of recurrent pericarditis.10  Since that time, several small 
studies have appeared analyzing the validity of his proposal.  Most of the studies looked into 
colchicine’s efficacy in preventing recurrent episodes; however, there are also studies that investigate 
colchicine in the initial, acute attack.  To date, there have been no completed and published double-
blinded randomized-controlled trials looking into colchicine as a therapy for acute or recurrent 
pericarditis.  
 The purpose of this paper is to perform a systematic review of the current literature on the 
treatment of pericarditis with colchicine.  Due to the limited amount of research on this topic, all 
aspects of pericarditis and colchicine will be considered.  Accordingly, the clinical question remains 
generalized and asks:  Is colchicine effective in the treatment of pericarditis?  In reviewing the current 
literature, the goal is to critically evaluate each selected study, qualitatively compile the results, and 
determine the safety and efficacy of colchicine in the treatment of pericarditis.  
 9 
 
Methods 
 
 
 A complete literature search was performed within the MEDLINE, CINAHL and Web of 
Science databases, using ‘pericarditis’ and ‘colchicine’ as the keywords.  Due to the limited amount of 
studies in this area, a broad search was conducted with only a few inclusion and exclusion criteria.  
The inclusion criteria were all multi-patient studies that analyzed colchicine for the treatment of acute 
or recurrent pericarditis from 1990 to present.  The exclusion criteria were any single-patient case 
reports, expert opinion articles, and studies that used intravenous colchicine or that focused solely on 
surgical patients.   Literature outside of the English language, not available in full text, or completed 
before 1990 was also excluded.  
 A JADAD scoring system is one method of uniformly critiquing multiple studies for a meta-
analysis or systematic review of literature.  This type of scoring system focuses mostly on randomized- 
controlled trials and does not intend to analyze different types of studies for a systematic review.  In 
anticipation of finding several different types of articles, an original method was developed to 
encompass multiple designs.     
 The MURDAD scoring method (appendix) is a more generalized approach to the 
heterogeneous literature.  The MURDAD system is not used as a basis to include or exclude articles, 
but is a way to give the higher scoring studies more weight when considering the results.  This validity 
measure is based on a ten point scale, as shown in Table Two, which sets the specific criteria to 
determine a score.  ‘Randomization’ is the only criteria worth two points, due to its strength at limiting 
bias.  The rest of the criteria are worth one point.  Table Two shows a complete breakdown of how all 
the articles scored on each MURDAD criterion.   
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Results 
 
 
 A total of five published articles met the inclusion and exclusion criteria through the systematic 
review (Table One).  The prospective literature included two randomized-controlled trials, one cohort 
study, and one case-series analysis.  One retrospective, multicenter case analysis also met the criteria.  
The publishing dates ranged from 1990 to 2006.  Each study focused on colchicine for the treatment of 
acute episodes of pericarditis or for preventing recurrence of this condition.  Various doses of 
colchicine were used throughout the studies.  For the most part, colchicine was administered in 
combination with other medications including:  NSAIDs, corticosteroids and immunosuppressants.  
All of the selected studies found colchicine to be effective in the treatment of pericarditis to some 
degree.  Some of the studies also determined that corticosteroids were an independent risk factor for 
recurrence of pericarditis.  Each study will be reviewed separately, discussing the validity (MURDAD 
score), subject population, specific intervention, comparison groups (where available), outcomes and 
secondary findings.  The articles will be addressed beginning with the highest validity score. 
 In Colchicine as First-Choice Therapy for Recurrent Pericarditis (CORE Trial, 2005), 
researchers constructed a randomized, open-label study which addressed the safety and efficacy of 
colchicine as an adjunct to conventional therapy for the first episode of recurrent pericarditis (second 
episode over-all).  The trial consisted of eighty-four subjects with a first episode of recurrent 
pericarditis.  They were randomly assigned to receive aspirin 800 mg orally every six or eight hours for 
seven to ten days, with gradual tapering for three to four weeks for the control group, or treatment with 
the same dose of aspirin combined with colchicine for the treatment group.  Colchicine was started at 
1.0 to 2.0 mg on day one, then 0.5 to 1.0 mg daily for six months as the maintenance dose.  The lower 
dose of colchicine was given to subjects weighing less than 70 kg.  When aspirin was not tolerated or 
contraindicated, prednisone was given at 1.0 to 1.5 mg/kg day for four weeks and gradually tapered.  
The prednisone patients were distributed equally among the control and treatment groups.  Recurrence 
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rate at eighteen months was the primary endpoint.  The colchicine arm had a lower recurrence rate 
compared to the control group (24.0% vs. 50.6%; p= 0.02; NNT=4.0).  As a secondary endpoint, the 
colchicine group appeared to have less symptom persistence at seventy-two hours (10% vs. 31%; p= 
0.03).  Additionally, corticosteroid use was an independent risk factor for recurrence (OR, 2.89; 95% 
CI, 1.10-8.26; p= 0.04).  There were no serious adverse reactions observed in the trial.  Three patients 
(7%) discontinued colchicine due to diarrhea.  This study received a MURDAD score of eight (Table 
Two). 
 In Colchicine in Addition to Conventional Therapy for Acute Pericarditis (COPE Trial, 2005), 
the same authors as the CORE trial formulated another randomized, open-label project to investigate 
the safety and efficacy of colchicine, when combined with conventional therapy for the treatment of 
the first episode of acute pericarditis.  In this study, 120 subjects with a first episode of acute 
pericarditis were randomly assigned to conventional treatment for the control group or conventional 
treatment plus colchicine for the treatment group.  Conventional treatment consisted of aspirin 800 mg 
orally every six or eight hours for seven to ten days, with gradual tapering for three to four weeks.  In 
the treatment group, colchicine was started as 1.0 to 2.0 mg for the first day, then maintained at 0.5 to 
1.0 mg/day for three months.  Corticosteroids were used in the same manner as the CORE trial and 
were distributed equally among both groups.  The primary endpoint was recurrence rate at eighteen 
months.  Colchicine reduced the recurrence rate at eighteen months (10.7% vs. 32.3%; p= 0.004; 
NNT= 5).  It also decreased symptom persistence at seventy-two hours compared to the control group 
(11.7% vs. 36.7%; p= 0.003).  Corticosteroid use was again an independent risk factor for recurrence 
(OR 4.30, 95% CI 1.21 to 15.25; p= 0.024).  There were no serious adverse reactions observed in the 
trial.  Five subjects (8.3%) discontinued colchicine due to diarrhea.  The COPE trial also received a 
MURDAD score of eight (Table Two). 
 In Therapy for Recurrent Acute Pericarditis: A Rheumatological Solution? (2006), researchers 
created a prospective, cohort or observational study of fifty-eight patients to assess the safety and 
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efficacy of a multidrug protocol for the treatment of recurrent pericarditis.  All fifty-eight patients were 
in an active episode of pericarditis and received NSAIDs of an undetermined dosage until they had a 
complete normalization of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).  If 
patients were taking corticosteroids, the researchers attempted to slowly taper them until discontinuing 
the medication where possible.  Hydroxychloroquine, azathioprine, cyclosporine or methotrexate 
(undetermined medication or dosage) were initiated if patients had difficulty with corticosteroid 
tapering.  Again, all patients received some form of the multidrug regime described above.  With this 
patient population, forty-four subjects were also treated with colchicine and fourteen were not.  
Colchicine was started at 0.5 mg daily for seven days, then 1.0 mg daily for one to two years.  The 
primary endpoint was attack rate, which was defined as the number of recurrences each patient had per 
month (attacks/patient/month).  In sum, the study compared the attack rate at the initial visit, at twelve 
months and at the end of follow-up (8.1 years).  After starting the multidrug protocol the attack rate 
dropped within the whole study from 0.48 to 0.03 attacks/patient/month (p<0.00001) by the first 
twelve months.  It stayed at approximately that same rate until the end of follow-up.  The forty-four 
colchicine patients experienced a decrease in attack rates from 0.54 to 0.03 attacks/patient/month 
(p<0.00001) at twelve months; and the fourteen non-colchicine patients dropped from 0.31 to 0.06 
attacks/patient/month (p= 0.002).  The decrease in attack rate was higher for the colchicine group (0.51 
attacks/patient/month) compared to the control group (0.25 attacks/patient/month) (p= 0.006).  There 
were no serious adverse reactions to colchicine.  Eight patients (16.3%) discontinued the medication 
due to side effects: seven from diarrhea and one from an unknown skin-rash.  This study received a 
MURDAD validity score of five (Table Two). 
 In Recurrent Pericarditis: Relief with Colchicine (1990), authors conducted a prospective case-
series of nine patients with pericarditis.  All of the subjects experienced at least three relapses despite 
treatment with acetylsalicylic acid, indomethacin, prednisone, or a combination of these medications.  
Patients were treated with colchicine at 1 mg/day and followed.  The length of follow-up for each 
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patient was different, ranging from ten to fifty-four months.  The primary endpoint was the mean 
interval between recurrences of pericarditis, recorded in months.  The researchers found that colchicine 
increased the time between relapses.  Before treatment with colchicine, the mean interval of recurrence 
was 3.33 +/- 4.3 months.  After treatment, the mean interval of recurrence was 24.3 +/- 16.1 months 
(p<0.002).  The subjects had no serious, adverse reactions to colchicine, and no subjects discontinued 
the medication due to side-effects.  The study received a MURDAD score of three (Table Two).   
 In Pretreatment with Corticosteroids Attenuates the Efficacy of Colchicine in Preventing 
Recurrent Pericarditis (2005), researchers completed a retrospective, multi-center, case-analysis of 
119 subjects, by collecting case reports from the previous fifteen years.  The subjects studied were 
required to have at least two documented relapses of pericarditis prior to any reported administration of 
colchicine.  After the two documented relapses, the patients had to have documented treatment with 
colchicine 1 mg/day.  The therapeutic trial of colchicine had to extend beyond any course of NSAIDs 
or tapering dose of corticosteroids.  This retrospective study required complete documented follow-up 
from the first episode of pericarditis (pre-colchicine), through the trials of colchicine.  The researchers 
compared recurrence rate while on colchicine versus recurrence rate after the discontinuation of the 
medication.  Only 18% (21/119) had recurrences during colchicine therapy and 30% (26/88) after its 
discontinuation.  Researchers identified previous use of corticosteroids (OR 6.68, 95% CI: 1.65-27.02) 
and male gender (OR 4.20, 95% CI: 1.16-15.21) as independent risk factors for the development of 
pericarditis.  This analysis did not document the number of serious adverse reactions or minor side 
effects of colchicine.  The study received a MURDAD validity score of two (Table Two). 
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Discussion 
 
 The purpose of this paper was to investigate the safety and efficacy of colchicine for the 
treatment of acute and recurrent pericarditis through a systematic review of the current literature.  Five 
articles from 1990-2006 met the inclusion and exclusion criteria.  The key points to discuss in this 
section are: general safety and efficacy of colchicine, secondary outcomes, validity, and the overall 
strength of this literature review. 
 All five studies found colchicine to be effective for the treatment of pericarditis in regards to 
the stated endpoints.  The COPE trial was the only study that had the specific intention of investigating 
colchicine as the initial treatment of pericarditis in its acute stage.3  The population consisted of 120 
subjects with the first episode of acute pericarditis who had never been treated for this condition in the 
past.3  Colchicine significantly decreased the symptom persistence at seventy-two hours and the 
recurrence rate at eighteen months (Table One).3  The CORE trial had just a few small differences in 
study design.  This study had eighty-four subjects with a first episode of recurrent pericarditis.  These 
patients had experienced pericarditis on one occasion in the past, and had then suffered a relapse, 
essentially a second attack.  The subjects were maintained on colchicine for six months (COPE trial 
patients were treated for 3 months).2  The CORE trial had the same endpoints.  Colchicine had similar 
results with decreasing the symptom persistence at seventy-two hours and recurrence rate at eighteen 
months.2  In having the same endpoints, both the CORE and COPE trials show the benefit of 
colchicine for the acute phase and in preventing recurrences of pericarditis.  The other three articles 
focused on the prevention of recurrence with colchicine.5, 7, 11  All three of the studies found colchicine 
to be effective at decreasing the rate of recurrence. 
 There were no serious, adverse reactions with the use of colchicine reported in any of the 
articles, although, one study failed to mention the absence or presence of side effects at all.  The most 
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common side effect was diarrhea, which went away shortly after discontinuing the medication.2, 3, 7  An 
unidentified rash was a rare side effect (occurred in only one patient) that also went away after 
stopping colchicine.7  These results show that colchicine is a fairly safe medication, even when taken 
long-term. 
 Three of the five articles found corticosteroids to be an independent risk factor for the 
recurrence of pericarditis, although there was little discussion as to why this was the case.2, 3, 11  The 
authors of the COPE trial spent the most time addressing this topic.  They speculated that the increase 
in recurrence rate with the use of corticosteroids may be due to the notion that pericarditis is mostly 
viral or idiopathic in origin.3  Moreover, corticosteroids may exacerbate the viral process, perpetuating 
pericardial inflammation and making recurrences more likely.3  While corticosteroids were at one point 
the treatment of choice for pericarditis, these studies suggest that they may not be the optimum choice, 
since it seems to make relapse more likely.  This finding makes continued study of colchicine, as a safe 
and effective alternative, all the more imperative. 
 The COPE and CORE trial were the only randomized studies and had greater strength of 
evidence with scores of eight.  Even the two strongest studies still had potential for significant bias not 
being of double-blinded design.  Additionally, the COPE trial documented five subjects that 
discontinued colchicine in the treatment arm, and the CORE trial mentioned three who also stopped the 
medication.3  However, the authors did not explain how this loss was accounted for in the statistical 
calculations, which could potentially make colchicine appear more efficacious than it really was.  None 
of the remaining three studies were randomized or blinded, and they all received fairly low MURDAD 
scores.  The studies’ limitations were typical for the type of study design used.  Table Two shows the 
specific limitations for each article. 
 The suggestion of colchicine as a treatment for pericarditis is limited by the amount of solid 
data.  There were no double-blinded, randomized-controlled trials, which left all of the studies 
vulnerable to significant potential bias.  Also, with the incidence of pericarditis being rather low 
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(although unclear) the subject samples were small, decreasing the power of each study.  However, all 
of the studies included in this systematic review found colchicine to be effective in the treatment of 
pericarditis.  There were no serious adverse reactions; the mild side effects that were reported resolved 
shortly after discontinuing the medication.   The results of this systematic review underscore the need 
for a large, double-blinded, randomized-controlled trial evaluating the efficacy and safety of colchicine 
in the treatment of pericarditis.      
 
 
Conclusion 
 
 
 Based on this systematic review of the current literature, there is moderate evidence to support 
the safety and efficacy of colchicine for the treatment of acute or recurrent pericarditis.  A larger, 
double-blinded, randomized-controlled trial is needed to further evaluate this proposition.  There is 
also evidence to support that corticosteroids are an independent risk factor for the recurrence of 
pericarditis.     
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Tables 
 
Article & Year Study Type & 
MURDAD 
Score 
 
Population 
 
Intervention 
&Side 
Effects 
 
Comparison 
 
Outcomes with 
colchicine 
 
Comments 
 
 
CORE Trial 
(2005) 
 
 
Prospective, 
randomized, 
open-label 
 
Validity Score 
= 8 
84 patients 
with a 1st 
episode of 
recurrent 
pericarditis 
 ASA plus 
colchicine 
0.5-1 mg/d x 
6 months 
3 patients 
(7%) stopped 
colchicine 
due to 
diarrhea 
Just ASA Lower recurrence at 18 
months 
24.0% vs. 50.6% 
(p=0.02) (NNT=4) 
Decreased persistence 
at 72h 
10% vs. 31% 
(p= 0.03) 
Corticosteroids 
independent 
risk factor 
OR 2.89 
95% CI 1.10-
8.26 
(p= 0.04) 
Used when 
ASA 
contraindication 
 
 
COPE  
Trial (2005) 
 
  
 
Prospective, 
randomized, 
open-label  
 
 
Validity Score 
= 8 
120 
patients 
with the 1st 
episode of 
acute 
pericarditis 
ASA plus 
colchicine 
0.5-1 mg/d x 
3 months 
5 patients 
(8.3%) 
stopped 
colchicine 
due to 
diarrhea 
 
   
Just ASA Lower recurrence at 18 
months 
10.7% vs. 32.3% 
(p=0.004) (NNT= 5) 
Decreased persistence 
at 72h 
11.7% vs. 36.7% 
(p= 0.003) 
Corticosteroids 
independent 
risk factor 
OR 4.30  
95% CI 1.21-
15.25 
(p=0.011) 
Used when 
ASA 
contraindication 
 
Therapy for 
Recurrent 
Pericarditis:  A 
Rheumatological 
Solution? (2006) 
Prospective 
Cohort 
(observational) 
Study 
 
Validity score 
= 5 
58 patients 
with 
pericarditis 
Multidrug 
therapy plus 
colchicine 
1mg/d x 1-2 
yrs 
8 patients 
(16.3%) 
stopped 
colchicine 
due to 
diarrhea/skin 
rash  
Multidrug 
therapy 
without 
colchicine 
Decreased basal attack 
rate 
(attacks/patient/month) 
colchicine group 
dropped from 0.54 to 
0.03 a/p/m  
(p<0.00001) 
Non-colchicine group 
dropped from 0.31 to 
0.06 a/p/m 
(p=0.002) 
 
Pretreatment 
with 
Corticosteroids 
Attenuates the 
Efficacy of 
Colchicine in 
Recurrent 
Pericarditis 
(2005) 
Retrospective, 
multi-center, 
case analysis 
 
Validity Score 
= 2 
119 
patients 
with 
pericarditis 
colchicine 
1mg/d 
 
Unknown 
drop-out due 
to side-effects 
Comparing 
patient 
recurrence 
rate with 
colchicine 
and after 
discontinuing 
Decreased recurrence  
 
18% had recurrences 
with colchicine 
 
30% had recurrences 
after discontinuation 
Corticosteroids 
independent 
risk factor 
OR 6.68 
95% CI 1.65-
27.02 
 
Recurrent 
Pericarditis:  
Relief with 
Colchicine 
(1990) 
Prospective 
case series 
 
Validity Score 
= 3 
9 patients 
with 
pericarditis 
colchicine  
1 mg/day 
No drop-out 
due to side-
effects 
Length of 
time between 
recurrences 
before/after 
colchicine  
Increased time between 
recurrences (months) 
Before tx 3.33 +/- 4.3m 
After tx 24.3 +/- 16.1 m 
(p<0.002) 
 
Table One:  Pertinent Data of the Articles Selected 
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 CORE Trial COPE  
Trial 
Therapy for 
Recurrent Acute 
Pericarditis: A 
Rheumatological 
Solution? 
Pretreatment 
with 
Corticosteroids 
Attenuates 
Efficacy of 
Colchicine in 
Preventing 
Recurrent 
Pericarditis 
Recurrent 
Pericarditis:  Relief 
with Colchicine 
Was the study 
randomized? (2pts) 
2 2 0 0 0 
Was the study double-
blinded? (1pt) 
0 0 0 0 0 
Sample size of at least 
50 subjects? (1pt) 
1 1 1 1 0 
Well-defined 
inclusion/exclusion 
criteria of pericarditis? 
(1pt) 
1 1 1 0 0 
Well-defined criteria for 
remission/recurrence of 
pericarditis? (1pt) 
1 1 1 0 0 
Sufficient length of 
follow-up? (1pt) 
1 1 1 0 1 
If subjects lost to follow-
up, was it accounted for 
in some way? (1pt) 
1 1 1 0 1 
Did each subject receive 
similar treatment other 
than what was being 
compared? (1pt) 
1 1 0 0 0 
Were the subjects 
similar at the start of the 
trial?  If not, was this 
accounted for in some 
way? (1pt) 
1 1 0 1 1 
 
Total Points (10pts) 
 
8 8 5 2 3 
Table Two:  Breakdown of the MURDAD Score for Each Article  
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Appendix 
 
 
 
Criteria Allowable Points Points Given 
Was the study randomized? 
 
2  
Was the study Double-
blinded? 
1  
Sample size of at least 50 
subjects? 
1  
Well-defined inclusion 
criteria of pericarditis? 
1  
Well-defined criteria for 
recurrence of pericarditis? 
1  
Sufficient length of follow-
up? 
1  
If subjects lost to follow-up, 
was it accounted for in 
some way? 
1  
Did each subject receive 
similar treatment other than 
what was being compared? 
1  
Were subjects similar at the 
start of the trial?  If not, was 
this accounted for in some 
way? 
1  
MURDAD Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
